Turkey

EFPIA-AIFD PUBLIC STATEMENT

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom pharmaceutical companies work provide valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.

Throughout the medicines life cycle pharmaceutical companies work with scientists and healthcare professionals. These collaborations are essential in addressing patient needs. Industry and healthcare professionals collaborate in a range of activities from clinical research to sharing best clinical practice and exchanging information on how new medicines fit into the patient pathway.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with healthcare professionals and organisations meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharma companies and HCPs/HCOs aims to building understanding of the collaboration and recognition of its value to patient care.

AIFD, EFPIA’s member association in Turkey has incorporated the EFPIA Disclose Code provisions into their national code. In the meanwhile, the Turkish competent authorities have adopted new Regulation requiring that pharma companies submit intended transfers of value to prior acceptance of the sponsorship by the healthcare professionals. Agreement on the transfer of value will then be communicated to the TITCK.

TITCK has indicated its preference for a single reporting point, and has therefore asked that companies disclose transfers of values within the frame of the Regulation, only to the Agency.

The EFPIA Board has therefore agreed to provisionally suspend full implementation of the EFPIA Disclosure Code in Turkey, whilst asking its Member Companies to communicate the transfers of value provided during 2016 to healthcare professionals and organisations in Turkey to the TITCK, as appropriate.

EFPIA and AIFD will continue dialogue with TITCK on further implementation and development of the Turkish Regulation with a view to reaching a level of transparency similar that what has now become general practice around Europe. Interactions between industry, HCPs and HCOs are vital to ensure we can continue to develop medicines that advance healthcare and continue to improve the lives of patients across Europe.